TG Therapeutics, Inc. (TGTX)
POSITIVEFondamentale
63
Prezzo
$55.94
Capitalizzazione
$8.21B
Parte 1 · Quanto vale l'azienda
Panoramica
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Per questa società non c'è ancora una scheda redazionale
Per questa società non c'è ancora un elenco di concorrenti.
Stato Patrimoniale e Liquidità
Ricavi
$800M
Ultimi 12 mesi (al 30/06/2026)
Utile Netto
$441M
Ultimi 12 mesi (al 30/06/2026)
Free Cash Flow
$-25M
Patrimonio Netto Totale
$648M
Passività Totali
$415M
Rapporto di Liquidità
4.27
Copertura Interessi
3.64
Debito/EBITDA
6.11
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$53.81
Prezzo Attuale
$55.94
Margine di Sicurezza
-4.0%
Range Fair Value
$36.39 - $71.24
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
20.44
ROE
69.0%
Rapporto P/B
14.19
P/FCF
493.15
Margine Lordo
82.4%
ROIC
7.8%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
7.8%
WACC
13.3%
ROIC − WACC
-5.5 pp
Il ROIC è sotto il costo del capitale: l'azienda distrugge valore per ogni dollaro investito.
Criteri di Analisi Fondamentale
Superati (16)
- EPS shows upward trend
- Price CAGR 27.86%
- ROIC 7.9%
- Gross Margin 82.4%
- Debt/Equity ratio
- Operating Margin 17.1%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 72.3%
- Revenue Growth 5Y 426.7%
- Analyst Consensus 86% Buy
- Net Margin Trend 55.2% vs 13.3%
Non superati (9)
- P/FCF 493.15
- P/B Ratio 14.19
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Unknown)
- Earnings Surprise avg -53.8%
- Earnings Quality (OCF/NI) 0.04
- Share Dilution 3.6%
- Piotroski F-Score 4/9
Non disponibili (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Segnali misti: alcune aree necessitano attenzione
Qualità degli Utili
Bassa qualità: indagare la contabilità
Diluizione Azionaria
Emissione nuove azioni, diluizione proprietà
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Mr. Michael S. Weiss Esq., J.D. | Chairman, CEO & President | 59 |
| Mr. Sean A. Power CPA | CFO, Corporate Secretary & Treasurer | 43 |
| Ms. Jenna Bosco | Senior Vice President of Corporate Communications | - |
| Mr. Adam Waldman | Chief Commercialization Officer | - |
Rischio Audit
9
Rischio CdA
10
Rischio Compensi
10
Rischio Diritti Azionisti
3
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Ultime Notizie
Ultime notizie per TGTX, da Markets Gazette.
- 6/18/2026POSITIVETG Therapeutics Stock Rises Thursday: What's Driving The Gains?
TG Therapeutics Inc. experienced a notable stock increase on Thursday, fueled by positive investor sentiment surrounding recent clinical trial updates for its drug BRIUMVI. The ongoing positive reception to these developments suggests that the market is factoring in potential future revenue streams and market share gains for BRIUMVI. This sustained upward momentum indicates strong confidence in the company's drug development pipeline and its commercial prospects, potentially leading to further analyst upgrades and increased institutional interest.
- 2/26/2026NEUTRALTG Therapeutics (TGTX) Q4 2025 Earnings Transcript
TG Therapeutics (TGTX) has released the transcript of its Q4 2025 earnings conference call. While the document is now available, specific financial figures, future outlook, and management commentary have not been disclosed or are currently inaccessible. Investors are keenly awaiting a detailed analysis of this information to assess the company's performance during the period and its projections for the upcoming fiscal year. The lack of concrete data prevents an immediate evaluation of the stock's impact, keeping market sentiment on hold pending further clarification.
via Markets Gazette